乳腺癌放疗中自动注量优化:平衡剂量学质量、危及器官保护与流程效率
该回顾性研究纳入35例左侧乳腺癌全乳照射患者,比较EZFluence(EZF)与3D-CRT、IMRT、VMAT的剂量学及计划效率。结果显示EZF靶区覆盖与VMAT相当,均匀性优于3D-CRT和IMRT,心脏和肺低剂量受量更低,对侧乳腺平均剂量小于1 Gy,且机器跳数少于IMRT和VMAT并降低计划者间变异。
要点
- EZF靶区覆盖与VMAT相当,均匀性优于3D-CRT和IMRT。
- EZF心脏平均剂量低于3D-CRT和IMRT,左肺低剂量体积优于IMRT和VMAT。
- EZF对侧乳腺平均剂量小于1 Gy,机器跳数少于IMRT和VMAT。
核心结论
- EZF在乳腺癌放疗中提供与VMAT相当的靶区覆盖,同时改善危及器官保护并避免不必要的对侧剂量。
- EZF自动化注量优化简化了计划流程,降低了计划者间变异,支持其融入常规临床实践。
研究设计与样本
- 回顾性分析纳入35例接受全乳照射的左侧乳腺癌患者。
- 对每例患者分别生成3D-CRT、IMRT、VMAT和基于EZF的前向计划野中野技术治疗计划。
- 分析靶区覆盖、心脏暴露、左前降支剂量、肺剂量和对侧组织剂量等剂量学参数,并通过机器跳数和计划时间评估计划效率。
主要发现
- EZF的剂量均匀性显著优于3D-CRT和IMRT,且交付的最大剂量更低。
- VMAT提供最高的计划靶区V95,EZF维持相当的靶区覆盖且高剂量区域显著减少。
- EZF的心脏平均剂量低于3D-CRT和IMRT;VMAT的高剂量心脏保护更优,但EZF减少了低剂量心脏扩散。
- EZF的左肺平均剂量和低剂量体积显著低于IMRT和VMAT。
- 3D-CRT和EZF的对侧乳腺平均剂量小于1 Gy,而IMRT和VMAT超过1 Gy。
关键数值与推荐
- EZF的机器跳数少于IMRT和VMAT,自动化计划流程减少了计划者间变异。
- 3D-CRT和EZF的对侧乳腺平均剂量小于1 Gy,IMRT和VMAT超过1 Gy。
临床怎么用
- 对于左侧乳腺癌全乳照射,可考虑采用EZF自动化注量优化以在保持靶区覆盖的同时降低心脏和肺低剂量受量。
- EZF可减少机器跳数和计划者间变异,有助于提高计划流程效率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In this study, we evaluated the effectiveness of EZFluence (EZF), an automated fluence optimization tool, in planning breast cancer radiotherapy by comparing its dosimetric performance with that of three-dimensional conformal radiotherapy (3D-CRT), intensity-modulated radiation therapy (IMRT), and volumetric-modulated arc therapy (VMAT). Specifically, we aimed to determine whether EZF can enhance target coverage, minimize dose to organs at risk, and improve planning efficiency. METHODS: This retrospective analysis included 35 patients who received whole-breast irradiation for left-sided breast cancer. Treatment plans were generated using 3D-CRT, IMRT, VMAT, and EZF-based forward-planned field-in-field techniques. Dosimetric parameters, including planning target volume coverage, cardiac exposure, left anterior descending artery dose, lung dose, and contralateral tissue dose, were analyzed. Planning efficiency was assessed by comparing the monitor units and planning time. RESULTS: EZF demonstrated significantly superior dose homogeneity and a lower delivered maximum dose compared with 3D-CRT and IMRT. Although VMAT provided the highest planning target volume V95, EZF maintained comparable target coverage with significantly reduced high-dose regions. Additionally, EZF achieved a lower mean heart dose compared with 3D-CRT and IMRT. While VMAT offered superior high-dose cardiac sparing, EZF minimized low-dose cardiac spread and significantly reduced the mean lung dose and low-dose volumes of the left lung compared with IMRT and VMAT. The mean doses to the contralateral breast with 3D-CRT and EZF were less than 1 Gy, whereas those when using IMRT and VMAT exceeded 1 Gy. Regarding efficiency, EZF required fewer monitor units than did IMRT and VMAT, and its automated planning process reduced inter-planner variability. CONCLUSION: EZF demonstrated significant potential as an innovative approach in breast cancer radiotherapy, providing comparable target coverage with enhanced sparing of organs at risk and without unnecessary contralateral dose. Its automated fluence optimization enhanced planning efficiency by simplifying planning and reducing variability. These findings support the integration of EZF into routine clinical practice to optimize radiotherapy delivery.
引用
- Choi YE, Shin HB, Sung K, et al. Automated fluence optimization in breast cancer radiotherapy: balancing dosimetric quality, organ-at-risk sparing, and workflow efficiency. Radiat Oncol. 2026. PMID: 41781988. doi:10.1186/s13014-026-02815-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。